NEW YORK – Lantheus on Thursday said the Prostate Cancer Clinical Trials Consortium will use its AI platform to identify imaging biomarkers and apply them to advance precision medicine research.
The collaboration between PCCTC and Lantheus subsidiary Exini Diagnostics involves the use of Lantheus' AI platform, which includes its US Food and Drug Administration-approved PSMA PET/CT imaging and bone scintigraphy devices. The platform assists in localization, segmentation, and quantification of potential lesions based on PET/CT imaging and the detection of hotspots for bone metastases based on bone scintigraphy scans.
PCCTC will use the platform in its early-phase studies to advance the discovery, development, and validation of novel AI-enabled biomarkers, which the group believes could help select patients for trials and evaluate their responses to targeted therapies.
"Lantheus believes its artificial intelligence platform can expand the utility of imaging diagnostics for precision medicine in prostate cancer and evolve from single-biomarker image analysis to an integrated clinical decision support system drawing on multiple biomarkers and clinical record data," Etienne Montagut, chief business officer of Lantheus, said in a statement. "This strategic partnership is a critical step forward to realize that vision."
Lantheus, based in North Billerica, Massachusetts, gained FDA approval for its PSMA-targeted PET imaging agent piflufolastat F 18 (Pylarify) last year to diagnose metastasis and recurrence in prostate-specific membrane antigen (PSMA)-positive prostate cancer patients. The firms' Pylarify AI platform assists in the evaluation of PET images of PSMA-positive lesions. In a clinical trial, the imaging agent detected at least one PSMA-positive lesion in 60 percent of prostate cancer patients who showed no evidence of metastasis in baseline conventional imaging.